Pfizer Inc. $PFE Shares Acquired by AMG National Trust Bank

AMG National Trust Bank increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 36.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 90,665 shares of the biopharmaceutical company’s stock after purchasing an additional 24,165 shares during the quarter. AMG National Trust Bank’s holdings in Pfizer were worth $2,546,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Penn Davis Mcfarland Inc. increased its position in Pfizer by 50.9% during the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after purchasing an additional 57,777 shares during the last quarter. Danske Bank A S purchased a new stake in shares of Pfizer during the 3rd quarter valued at $81,298,000. Vanguard Group Inc. increased its holdings in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after buying an additional 7,031,162 shares during the last quarter. KBC Group NV raised its position in shares of Pfizer by 8.3% in the 4th quarter. KBC Group NV now owns 9,193,713 shares of the biopharmaceutical company’s stock worth $228,924,000 after buying an additional 706,426 shares during the period. Finally, Pensionfund Sabic purchased a new position in shares of Pfizer in the 4th quarter worth $1,863,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $24.24 on Wednesday. The business’s 50-day simple moving average is $25.28 and its 200 day simple moving average is $26.18. The company has a market cap of $138.17 billion, a P/E ratio of 18.51 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the prior year, the business earned $0.92 EPS. Pfizer’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. Pfizer’s dividend payout ratio is 131.30%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Guggenheim lowered their price target on Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Finally, Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $28.50.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst coverage remains supportive, even after some modest price-target cuts. BMO kept an outperform rating and Guggenheim maintained a buy, suggesting Wall Street still sees upside from current levels. Benzinga analyst update
• Positive Sentiment: Pfizer’s oncology franchise is in focus ahead of Q2 results, with growth from key cancer drugs, biosimilars, and pipeline updates potentially helping offset declines in older medicines. Zacks oncology outlook
• Positive Sentiment: Investors are also encouraged by the long-term case for Pfizer’s Seagen integration, which some analysts argue could improve oncology growth and create durable value versus peers like Amgen. 247WallSt Pfizer vs. Amgen
• Neutral Sentiment: Pfizer’s dividend yield remains unusually high at about 7.1%, which may attract income investors, but it also raises questions about whether the payout reflects slower growth expectations. Motley Fool dividend article
• Negative Sentiment: Near-term earnings expectations are soft, with Wall Street looking for a double-digit decline in profit in the next quarterly report, reinforcing concerns about pressure on Pfizer’s core business. Barchart earnings preview
• Negative Sentiment: Drug-pricing headlines tied to the Trump administration are adding policy uncertainty across big pharma, including Pfizer, even though pipeline strength may ultimately matter more. Motley Fool drug-pricing article

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.